Adoption of new health products in low and middle income settings: how product development partnerships can support country decision making

Abstract

When a new health product becomes available, countries have a choice to adopt the product into their national health systems or to pursue an alternate strategy to address the public health problem. Here, we describe the role for product development partnerships (PDPs) in supporting this decision-making process. PDPs are focused on developing new products to respond to health problems prevalent in low and middle income settings. The impact of these products within public sector health systems can only be realized after a country policy process. PDPs may be the organizations most familiar with the evidence which assists decision making, and this generally translates into involvement in international policy development, but PDPs have limited reach into endemic countries. In a few individual countries, there may be more extensive involvement in tracking adoption activities and generating local evidence. This local PDP involvement begins with geographical prioritization based on disease burden, relationships established during clinical trials, PDP in-country resources, and other factors. Strategies adopted by PDPs to establish a presence in endemic countries vary from the opening of country offices to engagement of part-time consultants or with long-term or ad hoc committees. Once a PDP commits to support country decision making, the approaches vary, but include country consultations, regional meetings, formation of regional, product-specific committees, support of in-country advocates, development of decision-making frameworks, provision of technical assistance to aid therapeutic or diagnostic guideline revision, and conduct of stakeholder and Phase 4 studies. To reach large numbers of countries, the formation of partnerships, particularly with WHO, are essential. At this early stage, impact data are limited. But available evidence suggests PDPs can and do play an important catalytic role in their support of country decision making in a number of target countries.

Health technology assessment in low- and middle-income countries: a landscape assessment

“…In the coming years, HTA will also be critical in LMICs in view of the global health pipeline of new medicines and vaccines that are intended for direct introduction into these countries . Increasing institutional and human resource capacity for HTA can form the foundation for the product development partnerships that will be needed for successful evaluation and adoption of these new products in LMICs …”

Common characteristics of open source software development and applicability for drug discovery: a systematic review

“…Not only are PDPs familiar with the science behind the diseases, they are also experts in developing new medicines relevant for their target markets (inexpensive, durable and straightforward). They may also play a role in launching the product locally [ 77 ].…”

A four-step process for building sustainable access to diagnosis and treatment of Chagas disease

“…However, PDPs may confront internal divisions between those who would focus strictly on product development and those who favor a more proactive role in making sure products reach end users (23). Moreover, there is an ongoing risk of imbalances in control and responsibility between local actors in endemic countries and PDPs, whose staff and leadership may be concentrated in the Northern Hemisphere (23, 24).…”